763113-22-0 | Olaparib

Packsize	Purity	Availability	Price	Discounted Price
10mg	98%	in stock	$6.00	$4.00
100mg	98%	in stock	$10.00	$7.00
250mg	98%	in stock	$12.00	$9.00
1g	98%	in stock	$22.00	$16.00
5g	98%	in stock	$101.00	$71.00
25g	98%	in stock	$351.00	$246.00
100g	98%	in stock	$1,319.00	$923.00

Description

• Catalog Number: AB48261
• Chemical Name: Olaparib
• CAS Number: 763113-22-0
• Molecular Formula: C24H23FN4O3
• Molecular Weight: 434.4628
• MDL Number: MFCD13185161
• SMILES: O=C(N1CCN(CC1)C(=O)c1cc(ccc1F)Cc1n[nH]c(=O)c2c1cccc2)C1CC1
• NSC Number: 747856

Computed Properties

• Complexity: 790
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 32
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 4
• XLogP3: 1.9

Literature

• Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair.

  Nature genetics 20180801

• An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.

  BMC cancer 20160101

• 5-Fluorouracil-induced RNA stress engages a TRAIL-DISC-dependent apoptosis axis facilitated by p53.

  Oncotarget 20151222

• PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway.

  Molecular cancer therapeutics 20151201

• DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

  The New England journal of medicine 20151029

• Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.

  Journal of medicinal chemistry 20150910

• Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer.

  BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20150401

• Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle.

  Cell metabolism 20140603

• Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework.

  Nature reviews. Drug discovery 20140601

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

  Cancer discovery 20130101

• Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

  Cancer research 20121101

• Olaparib, PARP1 inhibitor in ovarian cancer.

  Expert opinion on investigational drugs 20121001

• Clinical trials and future potential of targeted therapy for ovarian cancer.

  International journal of clinical oncology 20121001

• Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells.

  EMBO molecular medicine 20121001

• [Ovarian cancer-criteria of response and the timing of regimen change in chemotherapy for ovarian cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20121001

• Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer.

  Current opinion in oncology 20120901

• Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.

  Breast cancer research and treatment 20120901

• Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

  Cancer discovery 20120901

• Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.

  Investigational new drugs 20120801

• Neoadjuvant treatments for triple-negative breast cancer (TNBC).

  Annals of oncology : official journal of the European Society for Medical Oncology 20120801

• Olaparib in platinum-sensitive ovarian cancer.

  The New England journal of medicine 20120712

• Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option.

  Breast cancer research and treatment 20120701

• BAP1 loss defines a new class of renal cell carcinoma.

  Nature genetics 20120701

• Current and emerging targeted therapies for metastatic breast cancer.

  Cancer 20120615

• Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases.

  Hepatology (Baltimore, Md.) 20120601

• Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.

  EMBO molecular medicine 20120601

• A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120415

• Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

  The New England journal of medicine 20120412

• PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma.

  Cancer research 20120401

• A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors.

  The oncologist 20120401

• [PARP inhibitors and breast cancer: update and perspectives].

  Bulletin du cancer 20120401

• Drug candidates derailed in case of mistaken identity.

  Nature 20120328

• Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120315

• A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors.

  Cancer science 20120301

• Synthetic lethality of cohesins with PARPs and replication fork mediators.

  PLoS genetics 20120301

• Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents.

  Neoplasia (New York, N.Y.) 20120301

• Present status and problems on molecular targeted therapy of cancer.

  Cancer research and treatment : official journal of Korean Cancer Association 20120301

• Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors.

  Nature biotechnology 20120219

• Plk1 and CK2 act in concert to regulate Rad51 during DNA double strand break repair.

  Molecular cell 20120210

• Structural basis of selective inhibition of human tankyrases.

  Journal of medicinal chemistry 20120209

• Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120201

• Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours.

  British journal of cancer 20120131

• Basal breast cancer: a complex and deadly molecular subtype.

  Current molecular medicine 20120101

• Ovarian cancer: opportunity for targeted therapy.

  Journal of oncology 20120101

• BRCAness profile of sporadic ovarian cancer predicts disease recurrence.

  PloS one 20120101

• Molecular basis of triple negative breast cancer and implications for therapy.

  International journal of breast cancer 20120101

• Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer.

  International journal of breast cancer 20120101

• Therapeutic strategies in epithelial ovarian cancer.

  Journal of experimental & clinical cancer research : CR 20120101

• Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer.

  PloS one 20120101

• Major clinical research advances in gynecologic cancer in 2011.

  Journal of gynecologic oncology 20120101

• Advances in using PARP inhibitors to treat cancer.

  BMC medicine 20120101

• Novel binding mode of a potent and selective tankyrase inhibitor.

  PloS one 20120101

• Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.

  Journal of oncology 20120101

• Metastasis of neuroendocrine tumors are characterized by increased cell proliferation and reduced expression of the ATM gene.

  PloS one 20120101

• Brain metastases from endometrial carcinoma.

  ISRN oncology 20120101

• The combination of olaparib and camptothecin for effective radiosensitization.

  Radiation oncology (London, England) 20120101

• Combination drug delivery approaches in metastatic breast cancer.

  Journal of drug delivery 20120101

• Full-exon pyrosequencing screening of BRCA germline mutations in Mexican women with inherited breast and ovarian cancer.

  PloS one 20120101

• The first European interdisciplinary ewing sarcoma research summit.

  Frontiers in oncology 20120101

• Targeting the fanconi anemia pathway to identify tailored anticancer therapeutics.

  Anemia 20120101

• Inhibition of poly(ADP-ribose) polymerase interferes with Trypanosoma cruzi infection and proliferation of the parasite.

  PloS one 20120101

• Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.

  Cell cycle (Georgetown, Tex.) 20111215

• The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment.

  Current drug targets 20111201

• Update on PARP1 inhibitors in ovarian cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20111201

• PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation.

  Oncotarget 20111201

• Poly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphoma.

  Nuclear medicine communications 20111101

• BRCA1 and BRCA2 mutations and breast cancer.

  Discovery medicine 20111101

• Melphalan as a treatment for BRCA-related ovarian carcinoma: can you teach an old drug new tricks?

  Journal of clinical pathology 20111001

• Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.

  Molecular cancer therapeutics 20111001

• PARP inhibitors--current status and the walk towards early breast cancer.

  Breast (Edinburgh, Scotland) 20111001

• Functional characterization of EMSY gene amplification in human cancers.

  The Journal of pathology 20110901

• Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

  The Lancet. Oncology 20110901

• Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110801

• An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110701

• Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110701

• Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

  The Journal of clinical investigation 20110701

• Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.

  Nature medicine 20110701

• PARP inhibitors: its role in treatment of cancer.

  Chinese journal of cancer 20110701

• The epistatic relationship between BRCA2 and the other RAD51 mediators in homologous recombination.

  PLoS genetics 20110701

• Epistatic relationships in the BRCA1-BRCA2 pathway.

  PLoS genetics 20110701

• Novel agents and future directions for refractory breast cancer.

  Seminars in oncology 20110601

• Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer.

  Nature reviews. Clinical oncology 20110501

• 5-Benzamidoisoquinolin-1-ones and 5-(ω-carboxyalkyl)isoquinolin-1-ones as isoform-selective inhibitors of poly(ADP-ribose) polymerase 2 (PARP-2).

  Journal of medicinal chemistry 20110414

• MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor.

  The Journal of biological chemistry 20110408

• A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours.

  British journal of cancer 20110301

• Synthesis and in vivo imaging of a 18F-labeled PARP1 inhibitor using a chemically orthogonal scavenger-assisted high-performance method.

  Angewandte Chemie (International ed. in English) 20110218

• Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110215

• Characteristics of triple-negative breast cancer.

  Journal of cancer research and clinical oncology 20110201

• 'Triple negative' epithelial ovarian cancer and pathologic markers for prognosis.

  Current opinion in obstetrics & gynecology 20110201

• Triple negative breast cancer: unmet medical needs.

  Breast cancer research and treatment 20110201

• Immunophenotypic predictive profiling of BRCA1-associated breast cancer.

  Virchows Archiv : an international journal of pathology 20110101

• Evaluation of the efficacy of radiation-modifying compounds using γH2AX as a molecular marker of DNA double-strand breaks.

  Genome integrity 20110101

• Breast cancer genome heterogeneity: a challenge to personalised medicine?

  Breast cancer research : BCR 20110101

• PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy.

  Acta clinica Belgica 20110101

• Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.

  Journal of hematology & oncology 20110101

• BRCA-deficient and triple negative breast cancers: is olaparib effective in both subtypes?

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20110101

• Concordant and opposite roles of DNA-PK and the 'facilitator of chromatin transcription' (FACT) in DNA repair, apoptosis and necrosis after cisplatin.

  Molecular cancer 20110101

• Targeted therapy in breast cancer: what's new?

  Swiss medical weekly 20110101

• Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.

  Cancer management and research 20110101

• Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells.

  BMC pharmacology 20110101

• Rare variants in the ATM gene and risk of breast cancer.

  Breast cancer research : BCR 20110101

• Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma.

  PloS one 20110101

• Drug therapy for hereditary cancers.

  Hereditary cancer in clinical practice 20110101

• Management options in triple-negative breast cancer.

  Breast cancer : basic and clinical research 20110101

• Genetic dissection of PARylation in the filamentous fungus Neurospora crassa.

  Methods in molecular biology (Clifton, N.J.) 20110101

• Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?

  Breast cancer research : BCR 20110101

• Platinum resistance in breast and ovarian cancer cell lines.

  Journal of experimental & clinical cancer research : CR 20110101

• MicroRNAs associated with metastatic prostate cancer.

  PloS one 20110101

• A de novo complete BRCA1 gene deletion identified in a Spanish woman with early bilateral breast cancer.

  BMC medical genetics 20110101

• Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines.

  BMC medical genomics 20110101

• Rad51 and BRCA2--New molecular targets for sensitizing glioma cells to alkylating anticancer drugs.

  PloS one 20110101

• Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil.

  PloS one 20110101

• Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review.

  International journal of surgical oncology 20110101

• Triple-negative breast cancer: adjuvant therapeutic options.

  Chemotherapy research and practice 20110101

• Multidrug resistance in breast cancer: from in vitro models to clinical studies.

  International journal of breast cancer 20110101

• Therapeutic targeting of cancer stem cells.

  Frontiers in oncology 20110101

• BRCA mutations in the management of breast cancer: the state of the art.

  Nature reviews. Clinical oncology 20101201

• [PARP inhibitors to treat triple negative breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101201

• The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.

  Blood 20101125

• Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.

  British journal of cancer 20101109

• Targeting poly(ADP-ribose) polymerase activity for cancer therapy.

  Cellular and molecular life sciences : CMLS 20101101

• Molecule of the month. Olaparib.

  Drug news & perspectives 20101101

• Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination.

  Nature structural & molecular biology 20101001

• Targeted therapies: PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations.

  Nature reviews. Clinical oncology 20101001

• Role for the mammalian Swi5-Sfr1 complex in DNA strand break repair through homologous recombination.

  PLoS genetics 20101001

• PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers.

  Current opinion in oncology 20100901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100901

• Beyond PARP inhibitors: agents in pipelines target DNA repair mechanisms.

  Journal of the National Cancer Institute 20100804

• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

  Lancet (London, England) 20100724

• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

  Lancet (London, England) 20100724

• [Treatment with oral agents for breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100701

• Society for biomolecular sciences - 16th annual conference & exhibition - advancing the science of drug discovery.

  IDrugs : the investigational drugs journal 20100601

• Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair.

  Molecular cancer therapeutics 20100601

• Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100520

• Multiple roles of BRIT1/MCPH1 in DNA damage response, DNA repair, and cancer suppression.

  Yonsei medical journal 20100501

• Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.

  Cancer research 20100215

• ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.

  Molecular cancer therapeutics 20100201

• A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100101

• The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer.

  Journal of oncology 20100101

• A current review of targeted therapeutics for ovarian cancer.

  Journal of oncology 20100101

• Targeted therapies in epithelial ovarian cancer.

  Journal of oncology 20100101

• Targeted therapy in ovarian cancer.

  Journal of oncology 20100101

• Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features.

  Breast cancer research : BCR 20100101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100101

• Biology-driven cancer drug development: back to the future.

  BMC biology 20100101

• Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future.

  Cancer journal (Sudbury, Mass.) 20100101

• Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms.

  Breast cancer research : BCR 20100101

• Does race affect outcomes in triple negative breast cancer?

  Breast cancer : basic and clinical research 20100101

• Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype.

  BMC cancer 20100101

• PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer.

  F1000 biology reports 20100101

• Treatment options for patients with triple-negative breast cancer.

  Journal of hematology & oncology 20100101

• Present and future evolution of advanced breast cancer therapy.

  Breast cancer research : BCR 20100101

• Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone.

  Breast cancer research : BCR 20100101

• Triple-negative breast cancer.

  Breast cancer research : BCR 20100101

• Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers.

  Breast cancer research : BCR 20100101

• Are current development programs realising the full potential of new agents?

  Breast cancer research : BCR 20100101

• New developments in treatment of ovarian carcinoma: focus on trabectedin.

  Cancer management and research 20100101

• Preclinical mouse models for BRCA1-associated breast cancer.

  British journal of cancer 20091117

• Converting cancer mutations into therapeutic opportunities.

  EMBO molecular medicine 20090901

• Triple-negative breast cancer: novel therapies and new directions.

  Maturitas 20090820

• Targeting the molecular defect in BRCA-deficient tumors for cancer therapy.

  Cancer cell 20090804

• Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90.

  Molecular cancer therapeutics 20090801

• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  The New England journal of medicine 20090709

• Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin.

  Cancer research 20090501

• Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.

  Breast cancer research : BCR 20090101

• BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?

  Journal of ovarian research 20090101

• Synthetic lethality: a framework for the development of wiser cancer therapeutics.

  Genome medicine 20090101

• PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?

  Breast cancer research : BCR 20090101

• Are current drug development programmes realising the full potential of new agents? The scenario.

  Breast cancer research : BCR 20090101

• Tailored targeted therapy for all: a realistic and worthwhile objective?

  Breast cancer research : BCR 20090101

• Recent advances in managing triple-negative breast cancers.

  F1000 medicine reports 20090101

• Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential.

  International journal of radiation oncology, biology, physics 20081115

• High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.

  Proceedings of the National Academy of Sciences of the United States of America 20081104

• 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

  Journal of medicinal chemistry 20081023

• A FlashPlate assay for the identification of PARP-1 inhibitors.

  Journal of biomolecular screening 20030601